Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$9.10 USD
-0.12 (-1.30%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $9.10 0.00 (0.00%) 5:22 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VIR 9.10 -0.12(-1.30%)
Will VIR be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for VIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIR
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
VIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
Other News for VIR
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
Vir gets FDA clearance, fast track designation for tobevibart and elebsiran
Vir Biotechnology: A Cautious Hold Amid Promising Prospects and Key Data Anticipation
Buy Rating Affirmed for Vir Biotechnology Amidst Promising Clinical Data and Strategic Leadership Enhancements
Notable Two Hundred Day Moving Average Cross - VIR